{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Laurberg JR"],"pubmed_abstract":["<h4>Background</h4>The standard treatment for non-metastatic muscle-invasive bladder cancer (stages T2-T4a) is radical cystectomy with lymphadenectomy. However, patients undergoing cystectomy show metastatic spread in 25% of cases and these patients will have limited benefit from surgery. Identification of patients with high risk of lymph node metastasis will help select patients that may benefit from neoadjuvant and/or adjuvant chemotherapy.<h4>Methods</h4>RNA was procured by laser micro dissection of primary bladder tumors and corresponding lymph node metastases for Affymetrix U133 Plus 2.0 Gene Chip expression profiling. A publically available dataset was used for identification of the best candidate markers, and these were validated using immunohistochemistry in an independent patient "],"journal":["BMC cancer"],"pagination":["638"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4164753"],"repository":["biostudies-literature"],"pubmed_title":["High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer."],"pmcid":["PMC4164753"],"pubmed_authors":["Jensen JB","Borre M","Laurberg JR","Orntoft TF","Dyrskjot L","Schepeler T"],"additional_accession":[]},"is_claimable":false,"name":"High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.","description":"<h4>Background</h4>The standard treatment for non-metastatic muscle-invasive bladder cancer (stages T2-T4a) is radical cystectomy with lymphadenectomy. However, patients undergoing cystectomy show metastatic spread in 25% of cases and these patients will have limited benefit from surgery. Identification of patients with high risk of lymph node metastasis will help select patients that may benefit from neoadjuvant and/or adjuvant chemotherapy.<h4>Methods</h4>RNA was procured by laser micro dissection of primary bladder tumors and corresponding lymph node metastases for Affymetrix U133 Plus 2.0 Gene Chip expression profiling. A publically available dataset was used for identification of the best candidate markers, and these were validated using immunohistochemistry in an independent patient ","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Aug","modification":"2025-04-04T11:31:23.971Z","creation":"2019-06-06T13:16:49Z"},"accession":"S-EPMC4164753","cross_references":{"pubmed":["25175477"],"doi":["10.1186/1471-2407-14-638"]}}